July 2008 Oncology News International

Treatment with tovorafenib appears well tolerated among pediatric patients with low-grade glioma, according to findings from the phase 2 FIREFLY trial.

Margaret Rosenzweig, PhD, CRNP-C, AOCNP, FAAN, discusses how nursling-led palliative care may improve advanced cancer care planning uptake based on a secondary analysis of the CONNECT study.

Nirogacestat also appears to improve progression-free survival compared with placebo among those with desmoid tumors in the phase 3 DeFi trial.

Rakhshanda Rahman, MD, FRCS, FACS, emphasizes the importance of educating patients and physicians on the potential risks and benefits of new approaches and technologies involved in the de-escalation of breast cancer treatment.

Rilvegostomig appears to yield no dose-limiting toxicities among patients with advanced or metastatic PD-L1–positive non–small cell lung cancer in the phase 1/2 ARTEMIDE-01 study.

Talazoparib plus enzalutamide appears to improve the objective response rate vs enzalutamide plus placebo among patients with metastatic castration-resistant prostate cancer harboring homologous recombination repair mutations in the phase 3 TALAPRO-2 study.